Tag
A prospective study demonstrates that tumor-informed ctDNA-based minimal residual disease (MRD) testing significantly predicts recurrence and survival in HPV-independent HNSCC, offering a median five-month lead time over clinical detection
A Phase II clinical trial demonstrates that combining tislelizumab with neoadjuvant chemotherapy significantly improves pathological response rates and organ preservation in patients with locally advanced head and neck squamous cell carcino
The Phase II/III INDUCE-3 trial was terminated early after the ICOS agonist feladilimab plus pembrolizumab failed to show superiority over pembrolizumab monotherapy in first-line recurrent or metastatic head and neck squamous cell carcinoma
This review analyzes the impact of individualized prognostic counseling on decisional conflict and regret in patients with head and neck squamous cell carcinoma, highlighting the efficacy of online prognostic tools in fostering shared decis
A meta-analysis of 11 trials shows that partial and major pathologic responses after neoadjuvant immunotherapy significantly correlate with improved disease-free survival in mucosal HNSCC, suggesting these metrics serve as viable surrogate
